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Summary
Rapamycin increases lifespan in mice, but whether this represents
merely inhibition of lethal neoplastic diseases, or an overall slow-
ing in multiple aspects of aging is currently unclear. We report
here that many forms of age-dependent change, including altera-
tions in heart, liver, adrenal glands, endometrium, and tendon, as
well as age-dependent decline in spontaneous activity, occur
more slowly in rapamycin-treated mice, suggesting strongly that
rapamycin retards multiple aspects of aging in mice, in addition to
any beneficial effects it may have on neoplastic disease. We also
note, however, that mice treated with rapamycin starting at
9 months of age have significantly higher incidence of testicular
degeneration and cataracts; harmful effects of this kind will guide
further studies on timing, dosage, and tissue-specific actions of ra-
pamycin relevant to the development of clinically useful inhibitors
of TOR action.
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Introduction
Rapamycin has been found, in five laboratories (Chen et al., 2009; Harri-
son et al., 2009; Anisimov et al., 2010, 2011; Miller et al., 2011), to
extend mouse lifespan. These observations are consistent with two
broadly distinct explanations: rapamycin might (i) slow aging or (ii) retard
lethal neoplasia. The idea that rapamycin slows aging per se is consistent
with the observation that genetic or pharmacological inhibition of TOR
(mTOR, target of rapamycin, FRAP1), the kinase target of rapamycin, can
extend lifespan in worms and flies (Vellai et al., 2003; Jia et al., 2004; Ka-
pahi et al., 2004), in which lifespan is not typically limited by neoplasia,
and with the observation that several aspects of aging are retarded in
mice lacking S6K, a TOR target that mediates some of its effects on cell
proliferation and stress resistance (Selman et al., 2009). The idea that ra-
pamycin extends mouse lifespan principally by blocking tumor develop-
ment is consistent with studies showing rapamycin-mediated growth
inhibition of many forms of cancer (Hidalgo & Rowinsky, 2000). Cancer is
frequently the cause of death in both control and rapamycin-treated
mice, although the rapamycin-treated mice are older at the time of death,
suggesting that this agent may be extending lifespan by delaying cancer
incidence or slowing its progression (Harrison et al., 2009; Miller et al.,
2011). The two classes of explanation are not mutually exclusive: rapamy-
cin might both retard neoplasia and also slow aspects of aging that are
not reflections of neoplastic disease.
To test the idea that rapamycin retards aging in mice, we evaluated a
series of age-sensitive outcomes in 20–22-month-old mice, that is, at an
age where relatively few mice in the control or rapamycin-treated cohorts
have died. We used a genetically heterogeneous mouse model with a
wide range of age-related pathologies rather than a few strain-specific
characteristics, including tests of the adrenals, heart, liver, tendons, eye,
lung, and reproductive organs, toward the goal of testing the idea that
rapamycin might slow aging effects on many tissues and thus by infer-
ence slow the aging process per se. We also focused on lesions that are,
for the most part, unrelated to cancer biology and also unlikely to lead to
death in mice, because we wished to mitigate effects prior to 22 months
and because testing the general hypothesis requires evaluation of tissues
above and beyond the neoplastic lesions that usually lead to death of
these mice. We evaluated mice treated with a dose of rapamycin,
14 ppm in food, that has been shown to extend lifespan, as well as two
other doses (4.7 and 42 ppm) for which lifespan studies are currently in
progress. Although our main goal was to see whether age-sensitive
changes occurred more slowly in rapamycin-treated mice, the data set
also gave us an opportunity to look for harmful side effects of rapamycin
treatment, side effects that might complicate attempts to use strategies
of TOR inhibition to slow aging in clinical settings.
Results
Male and female mice exposed to rapamycin at doses of 4.7, 14, or
42 ppm from age 9 months were euthanized at 22 months of age for a
detailed necropsy analysis. Young (4 month) control mice from the same
genetically heterogeneous cross and old control mice without rapamycin
treatment were evaluated in parallel by a board-certified veterinary
pathologist (JW) who was blind to the rapamycin status. We noted four
classes of lesions that were age-sensitive and in which the aging effect
was opposed by rapamycin in males, females, or both sexes.
Liver degeneration
The occurrence of lipid filled vesicles at multiple foci within the hepatic
parenchyma (multifocal macrovesicular lipidosis) was noted in 67% of
the old male control mice, but in none of the young controls (P < 0.001
for age effect). Representative images of this lesion are shown in
Fig. S1A,B. This lesion was seen in only 20% of the old females (nonsig-
nificant compared with young females). A comparison among the four
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groups of old male mice (rapamycin at 0, 4, 14, and 42 ppm) showed a
significant effect (P = 0.02, trend test for ordered categories). As shown
in Fig. 1A, rapamycin leads to a dose-dependent decline in the incidence
of liver degeneration in male mice, and the effect is dose dependent.
Atypical nuclei in cardiac myocytes
Twenty three per cent of young mice and 70% of old control mice had
abnormalities of nuclear size and chromatin conformation in the myocar-
dium (both sexes combined). Figure S1C,D shows representative sec-
tions, characterized by enlarged round or oval nuclei with clumped
chromatin; more severe lesions include large multinucleated cells. The
age effect, comparing young to old controls, was significant at
P = 0.001. Rapamycin doses between 4.7 and 42 ppm were equally
effective at lowering the incidence of these atypical nuclei (Fig. 1B),
diminishing the frequency to 40 ⁄ 80 = 50% compared with 21 ⁄ 30
among old controls. This difference is significant by the one-sided Fisher’s
Exact Test at P = 0.047.
Endometrial cystic hyperplasia
This lesion, that is, the growth of multiple large cysts within the uterine
lining, was seen in 1 ⁄ 15 (7%) of young female controls, and in 13 ⁄ 15
(87%) of old female controls (P < 0.001). Representative sections are
shown in Fig. S1E,F. Neither of the two lower rapamycin doses produced
a significant diminution of the incidence of this lesion, but the highest ra-
pamycin dose did lower the incidence (8 ⁄ 15 = 53%, P = 0.05 compared
with old controls; see Fig. 1C).
Adrenal tumors
Adrenal tumors were seen in 1 ⁄ 30 young mice (3%) and in 6 ⁄ 30 old con-
trol mice (20%), with both sexes combined. The incidence among rapa-
mycin-treated mice was 5 ⁄ 80 = 6%, and this proportion differs from
that of the old control group at P = 0.04 by the one-sided Fisher Exact
Test. A test for trend among ordered groups (rapamycin doses of 0, 4.7,
14, 42 among the old mice) showed a significant trend at P = 0.03. Fig-
ure 1D shows the proportion of mice with adrenal tumors. It is worth not-
ing that adrenal tumors rarely contribute to death in UM-HET3 mice; only
1 ⁄ 31 control mice, and 0 ⁄ 40 rapamycin-treated mice were judged to
have died because of adrenal tumors in an end-of-life necropsy series
(Harrison et al., 2009).
Figure S1G,H shows representative sections.
The necropsy analysis showed significant age-dependent increases in
adrenal hyperplasia (males only), adrenal telangectasia (i.e., dilation of
blood vessels in the adrenal medulla), ovarian cyst (females only), thyroid
cold follicles (i.e., large follicles filled with colloid that do not respond to
thyroid-stimulating hormone), and lung tumor (Fig. 2); rapamycin-trea-
ted mice had a trend toward lower incidence rates for four of these five
lesions, but the difference between untreated and rapamycin-treated
Fig. 1 Incidence of liver degeneration (males only), myocardial nuclear atypia, endometrial hyperplasia (females only), and adrenal tumor in young, old, and rapamycin-
treated mice. Group sizes were as follows: young, old, and Rapa-Low, 15 of each sex; Rapa-Mid 14 females and 12 males; Rapa-High, 13 females and nine males. Fisher’s
Exact Test was used to evaluate the significance of age effects (young vs. old untreated), to compare Rapa (all doses) vs. old (untreated), or to compare old untreated vs.
Rapa-high as indicated in the figure panels. Cuzick’s nonparametric test for trends (Cuzick, 1985) was used to evaluate significance of differences among the four groups of
old mice at rapamycin doses (zero, low, mid, or high).
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mice was not statistically significant in any of these cases. Figure S2
shows stained sections of these four forms of pathology.
Age effects on tendon
Tendons stiffen and lose elasticity in a region-dependent manner during
aging in mice and humans (Wood et al., 2011). To see whether rapamy-
cin treatment slows this age-associated change, tibialis anterior (TA) ten-
dons were dissected from mice euthanized at 22 months of age and
evaluated for maximum tangent modulus (an index of resistance to
stretching) and for hysteresis (an index of the extent to which tendons
recover their original length as they return to an unstretched condition).
The proximal section of the TA tendon (i.e., the section closest to the
muscle and furthest from the bone attachment site) showed a significant
age-dependent increase in maximum tangent modulus and decrease in
hysteresis comparing young to old control mice (Fig. 3), and both age
effects were significantly smaller in rapamycin-treated mice.
Thus, in summary, rapamycin significantly reduced the incidences of
liver degenerative change, myocardial nuclear abnormalities, endometrial
hyperplasia, and nonlethal adrenal tumors in 22-month-old mice, dimin-
ished the effects of aging on the biomechanical properties of tendon, and
produced a numerical decrease in four of five other age-sensitive nec-
ropsy findings that did not achieve statistical significance.
Rapamycin increases cataract severity
Cataract severity was scored on a scale of 0–3 by slit lamp examination in
unanesthetized mice at 20 months of age by an ophthalmologist (MW)
who was unaware of the treatment condition. Scores for left and right
eyes were highly correlated, and an average score was thus used as an
index of cataract severity for each mouse. No cataracts were seen in
young controls (Score = 0). Cataract scores increased by 20 months in
females (P = 0.0002 compared with young), with a similar trend in males
(P = 0.06). In the old mice (20 months), mean cataract score was signifi-
cantly higher in females (0.61 ± 0.14, N = 24) than in males
(0.10 ± 0.05, N = 24; P = 0.002), and so rapamycin effects were evalu-
ated separately in each sex. The results (Fig. 4), comparing rapamycin
doses of 0 (old controls), 4.7, 14, and 42 ppm, showed a significant effect
for dose-dependent increase in both males (P = 0.014) and females
(P = 0.001). When old control mice are excluded to confine the analysis
to mice that received at least some rapamycin, the trend test is still signifi-
cant for females (P = 0.01), but not for males.
Sections of three control eyes and four eyes from rapamycin-treated
mice were evaluated histologically. Figure S3 illustrates the histological
findings. Only the lenses were affected in ocular sections. Both control
and rapamycin-treated eyes had evidence of mild posterior subcapsular
changes, but only the specimens from the rapamycin group had evidence
of cortical cataract, characterized by globular degeneration, that is,
aggregation of lens crystallins (blue arrows, upper panels); posterior epi-
thelial migration, especially below the bow region (curve arrows, upper
right panel); and evidence of calcification (black arrows, lower panels).
Although this survey is limited to a small number of specimens, it provides
an initial suggestion of TOR-dependent processes that might contribute
to maintenance of lens transparency in the second half of the lifespan.
Rapamycin increases testicular degeneration in male mice
The necropsy series illustrated in Figures 1 and 2 found one age-depen-
dent change that was more severe in rapamycin-treated mice than in old
controls, that is, testicular degeneration in males (Fig. 5). Testicular
degeneration is characterized by a progressive loss of spermatids, sper-
matocytes, differentiating spermatogonia and primary spermatogonia.
The degeneration follows an orderly loss of all stages of spermatogenesis
from the most mature to least differentiated cells. Lumens of tubules
often contain multinucleate giant cells, dead cells from different stages,
and debris. Vacuolation of immature sperm cells is also prominent in
many of the degenerating tubules. The lesion begins in small foci and pro-
gresses to involvement of all tubules. Degeneration was seen in 2 ⁄ 15
control males (13%), but in 30 ⁄ 36 (83%) of males in the rapamycin-trea-
ted groups (P < 0.001), with full effects apparent even in those mice
receiving the lowest rapamycin dose. The degree of degeneration was
recorded on a scale of 0–4. Analysis of variance among the four groups
of 20-month-old mice showed a significant difference among
groups (P < 0.0001), and a post hoc Sidak test showed that the order of
groups was Old < R-Low = R-Mid < R-High.
Fig. 2 Incidence of adrenal hyperplasia, adrenal telangectasia, ovarian cyst (females only), thyroid cold follicles, and lung tumor in young, old, and rapamycin-treated old
mice (pooled across rapamycin doses). The bracket in each figure indicates a significant difference between young and untreated old mice by Fisher’s Exact Test.
Fig. 3 Maximum tangent modulus (left) and hysteresis area (right) for tibialis
anterior tendons. Bars show mean ± SEM for N = 6 young, 9 old, and 17–20 old
rapamycin-treated mice. Young values differed from old at P = 0.002 for each
endpoint by t-test. Old differed from rapamycin treatment group at P = 0.036 for
maximum tangent modulus and at P < 0.001 for hysteresis area.
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Spontaneous activity
We have previously reported (Miller et al., 2011) that rapamycin, at
14 ppm, retarded the age-related loss of spontaneous activity
between 7 and 18 months of age, but this change was seen only in
male mice, and with significant site-to-site variation among mice
housed at the University of Michigan (UM), the University of Texas
Health Science Center in San Antonio (UT), and the Jackson Labora-
tory (TJL). In this study, we have measured spontaneous activity at
both ages in independent cohorts of mice in the context of an
ongoing longevity study at rapamycin doses of 4.7, 14, and 42 ppm.
A change score, calculated as activity at 18 months minus activity at
7 months, was calculated for each animal for which scores at both
ages were available, and mean values are shown in Fig. 6, pooling
across the three test sites. For males, rapamycin at the middle dose,
14 ppm, led to a significant diminution of the age-related decline in
spontaneous activity, replicating the published study in an indepen-
dent cohort. Each of the other two rapamycin doses also reduced
the age effect, but not to a significant degree. In females, the high-
est rapamycin dose, 42 ppm, led to a significant reduction in the
age effect on spontaneous activity. There was considerable site-to-
site variation (not shown), but in aggregate the pooled data suggest
that rapamycin may retard age-dependent changes in activity. The
basis for the change in movement with age is not well understood
in rodents or humans and seems likely to involve a variety of
changes in motivation, weight, muscle strength, and hormonal tone,
but can be interpreted as one measure of integrated physiological
function whose rate of decline seems to be rapamycin sensitive.
Rapamycin levels in peripheral blood
To confirm the idea that rapamycin levels in serum would be propor-
tional to the dose of rapamycin provided to the mice, a separate
group of UM-HET3 animals was placed on diets with 4.7, 14, or
42 ppm rapamycin at age 3–4 months of age, with 12–14
mice ⁄ group, and serum was taken 5 months later for rapamycin
quantification using methods described in (Harrison et al., 2009). Fig-
ure 7 shows rapamycin levels in individual mice. Average values for
the three groups were, respectively, 6.5 ± 1.1 (mean ± SEM),
13.4 ± 2.6, and 57.5 ± 13.2. Thus, serum rapamycin levels rose in
proportion of dose of this agent in chow, though with considerable
variation among mice.
Fig. 4 Cataract severity in mice evaluated by slit lamp examination at 20 months of age. Each eye was scored on a scale of 0–3, and the mean value of the left and right eye
was used as the index of severity for each mouse. Bars shown mean ± SEM for groups of 25–29 female mice or 17–30 male mice. Significance of the trend among four
groups of 20-month-old mice (old, Rapa-low, Rapa-mid, and Rapa-high) was evaluated by the nonparametric method of Cuzick (Cuzick, 1985).
Fig. 5 Testicular degeneration in males. Group sizes as in Fig. 1, with statistical
evaluation as in (Cuzick, 1985).
Fig. 6 Age-associated decline of spontaneous in-cage activity, calculated as a
change score (· 10)3) for each mouse tested at both 7 and 18 months of age. Bars
show means ± SEM, and asterisks indicate significant effects of rapamycin
treatment at P < 0.05, as estimated using a two-factor ANOVA with Site (UT, UM,
TJL) and Rx (rapamycin or untreated) as the predictor variables.
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Discussion
Our results show that rapamycin-treated mice are delayed in the develop-
ment of many forms of age-related pathology, including degenerative
changes in the liver and heart, proliferative lesions of endometrium and
adrenal gland, and alterations in tendon elasticity. The age-dependent
decline in spontaneous activity was also diminished in rapamycin-treated
mice, although the effective dose differed between males and females. In
addition, five other lesions, affecting lung, adrenal gland, ovary, and thy-
roid, increased in incidence between 4 and 22 months of age, and four
of these five showed a trend toward lower frequency in rapamycin-trea-
ted mice than in untreated controls, though these effects did not reach
statistical significance. Taken together, these findings support the
hypothesis (Blagosklonny, 2006) that the aging process is delayed by
rapamycin in genetically heterogeneous mice.
Neoplastic disease is responsible for over 80% of the deaths of ra-
pamycin-treated mice in our longevity population (Miller et al., 2011),
suggesting that longevity extension in these mice might reflect inhibi-
tion of multiple forms of neoplastic disease, rather than an effect on
the aging process per se. Our new data do not disprove this idea;
rapamycin may well both slow multiple aspects of aging and also
have a direct anti-tumor effect, with the latter effect predominantly
responsible for lifespan extension in these cancer-prone mice. It is
also possible that the reduced cancer incidence could itself be a con-
sequence of delayed aging, through mechanisms still to be defined.
The finding that rapamycin started at 9 months of age does not pro-
vide significantly greater longevity effect than this drug started at
20 months (Miller et al., 2011) also suggests that the major impact
on lifespan is via modulation of processes that operate only after
20 months of age, with induction or progression of neoplasia an
obvious suspect. Demographic analyses of our longevity cohorts
(Miller et al., 2011) have shown that rapamycin, at 14 ppm, produces
a significant change in both parameters of the Gompertz distribution,
that is, both age-dependent and age-independent effects on mortality
risk, each of which might involve direct or indirect effects on cancer
cell biology and host defenses against cancer. It will be of interest to
determine whether rapamycin extends lifespan in strains of mice in
which deaths because of cancer account for a smaller fraction of
lethal illnesses and reduce age-related diseases and functional declines
in other vertebrate species.
The idea that TOR inhibition might lead to a delay in aging, and thus in
many age-associated dysfunctions, is consistent with work in invertebrate
organisms. Mutations that diminish TOR function extend lifespan in flies
(Kapahi et al., 2004) and nematodes (Vellai et al., 2003; Jia et al., 2004).
Inhibition of TOR also extend lifespan in models of both replicative and
chronological lifespan in yeast (Kaeberlein et al., 2005; Powers et al.,
2006). There is also good evidence for diminished TOR activity, at least in
liver, of mice in which the aging process has been decelerated either by
mutation of genes needed for GH and IGF-1 production (Sharp & Bartke,
2005), or by caloric restriction (Sun et al., 2009). Evidence (Selman et al.,
2009) that deletion of ribosomal S6 protein kinase 1, an important media-
tor of TOR action, not only extends lifespan in female C57BL ⁄ 6 mice, but
also slows age-related changes in T cells, behavioral traits, and bone
structure is also consistent with our observations of rapamycin-treated
mice. Evidence is also beginning to accumulate that rapamycin can
reverse or retard age-related change in clinically relevant model systems,
including studies of B cell production and influenza vaccine responses
(Chen et al., 2009), and of b-amyloid and tau accumulation in CNS tissue
(Caccamo et al., 2010).
Some of the specific histopathology endpoints used as markers of
aging in this study deserve further comment. The age-dependent liver
lesion seen in controls was a multifocal to diffuse, centrilobular, macrove-
sicular lipidosis. Macrovesicular lipidosis can be induced by a number of
xenobiotics, although xenobiotics generally induce a mixed change with
both microvesicular and macrovesicular lipidosis (Thoolen et al., 2010). In
our study, rapamycin blocked this age effect, reducing the incidence of
hepatic lipidosis in a dose-dependent manner in males. Increased expres-
sion of liver enzymes involved in the detoxification of xenobiotics has
been observed in long-lived mutant mice with defects in growth hormone
production (Amador-Noguez et al., 2007), and we have unpublished
data that mRNA for these enzymes is elevated within 3 months of rapa-
mycin treatment in UM-HET3 mice (M. J. Steinbaugh and R. A. Miller,
unpublished data). Resistance to the effects of xenobiotic hepatotoxins
may be a common theme in both genetic and pharmacological models of
slowed aging.
Aging changes and degeneration in cardiac myocytes were character-
ized primarily by nuclear atypia. Nuclei were enlarged, oval to round, hy-
perchromatic and occasionally clustered. Some of the nuclei had a dense
central longitudinal bar similar to that characteristic of Anitschkow cells.
Previous studies have associated nuclear atypia with cell cycle abnormali-
ties and alterations in mitochondrial function, both known to increase
with age (Ahuja et al., 2007). A small number of our mice had evidence
of myofiber degeneration and vacuolization, but the lesions were not
associated with treatment.
Rapamycin led to significant inhibition of endometrial hyperplasia
and adrenal tumors, and to statistical nonsignificant trends toward
lower levels of adrenal telangectasia, thyroid follicles, and ovarian
cysts. Cystic endometrial hyperplasia is the most common spontane-
ous lesion of the uterus in aged female mice (Davis et al., 1999).
Both the number and size of glands are increased and many of the
glands are cystic and filled with serous fluid. The lesion is not preneo-
plastic. Cystic endometrial hyperplasia has been associated with
changes in the estrous cycle (Davis et al., 1999). Subcapsular hyper-
plasia of the adrenal cortex is also a common lesion in aging mice
(Mohr et al., 1996). In our UM-HET3 mice, this lesion was common
and severe and included both Type A (spindle) cells and Type B
(polygonal) cells. Subcapsular hyperplasia has been associated with
alterations of hormones associated with aging (Mohr et al., 1996). In
addition, there was an increase in adrenal cortical adenomas, from
3% in young mice to 20% in aged controls (not statistically
Fig. 7 Rapamycin levels in blood of mice tested at age 8–9 months after
consumption of rapamycin for 5 months. Each symbol shows an individual mouse,
and horizontal bars indicate means.
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significant), that were significantly lower in mice treated with rapamy-
cin (Fig. 1D). An inhibition of adenoma and carcinoma incidence is
consistent with other lines of evidence that rapamycin may inhibit
neoplastic disease, although cancer of the adrenal very seldom leads
to death in the UM-HET3 stock.
We have also observed that rapamycin-treated mice have more
severe cataracts and have a higher incidence of testicular degenera-
tion in males. Because TOR is involved in a very wide range of cellular
responses to proliferative, nutritional, and stress signals, it is hardly
surprising that blocking TOR signals throughout the lifespan may pro-
duce side effects that impair function in some tissues. Rapamycin
started at 20 months of age produces equivalent lifespan extension,
in UM-HET3 mice, as it does when started at 9 months of age (Miller
et al., 2011), and it may prove that the optimal ratio of benefit to
harmful side effects will involve starting the drug in mice older than
9 months or may require an intermittent schedule in which months
without drug exposure are alternated with months in which rapamy-
cin is provided (Anisimov et al., 2011). It is also still unclear as to
whether the benefits of rapamycin treatment depend on TOR inhibi-
tion per se, or on compensatory changes in other pathways called
into play by diminished TOR function; in the latter case, it may be
possible to devise interventions that further improve the ratio of posi-
tive to negative effects on health.
An effect of rapamycin on cataract development has not, so far as we
know, previously been noted in rodents or in humans. Rapamycin has
been shown to diminish proliferation of lens epithelial cells in culture, to
block migration of these cells in response to fibroblast growth factor, and
to increase the ratio of Bax ⁄ Bcl-2 in these cells, perhaps predisposing
them to apoptosis (Liu et al., 2010; Wang & Wang, 2011), but whether
these effects contribute to cataract development will require further
evaluation.
Testicular tubular degeneration is a common lesion in aging males
(Radovsky et al., 1999). The lesion is characterized by degenerate and
necrotic spermatogenic cells. Multiucleate giant cells are also a com-
mon feature. In advanced cases, only a few Sertoli cells and occa-
sional spermatogonia remain. In our population, this lesion increased
greatly in severity in rapamycin-treated males, although whether the
mechanism of age-related change involves TOR function in one or
more testicular cell types is not known. Spermatogenesis and fertility
are impaired in men receiving rapamycin in the context of therapeutic
transplantation (Zuber et al., 2008).
To sum up, the claim that a particular gene or diet or drug slows
aging should include evidence for retardation of age effects on prolif-
erating cells, nonproliferating cells, and extracellular structures,
because aging modulates the pace of decline in each of these
domains. The conclusion that caloric restriction slows aging was
based not only on lifespan data, but also in large part on evidence of
this kind (Weindruch et al., 1986; Weindruch & Sohal, 1997). Simi-
larly, data showing that pituitary dwarf mice show slower rates of
change in tumors, cognitive function, renal pathology, and cataracts
(Flurkey et al., 2001; Kinney et al., 2001a,b; Ikeno et al., 2003; Verg-
ara et al., 2004) have strengthened the case for delayed aging in
these genetic models as well. In addition to its effects on the pace of
lethal neoplasia (Harrison et al., 2009; Miller et al., 2011), rapamycin
now seems to retard age effects on tendon, liver, myocardium, and
endometrium (this report), and in bone marrow (Chen et al., 2009).
Although clearly a good deal of additional work will be needed to
establish the range of age effects that are or are not modulated by
rapamycin, it now seems safe to conclude that TOR inhibition does
indeed slow aging in mice. The observation that inhibition of TOR
can extend lifespan in worms, flies, and yeast, species in which neo-
plasia is not an important cause of death, is consistent with the idea
that linkage of TOR-dependent processes to aging rate has deep evo-
lutionary roots, even though the details by which age-dependent




All the mice used in this project were of a genetically heterogeneous
stock, called UM-HET3 in previous publications, produced by a cross
between (BALB ⁄ cByJ · C57BL ⁄ 6J)F1 mothers (JAX stock #100009)
and (C3H ⁄ HeJ · DBA ⁄ 2J)F1 fathers (JAX stock #100004). Each mouse
in the population is thus genetically unique, and a full sib, with
respect to nuclear genes, to all other members of the UM-HET3
stock. Husbandry and diet details were as described in earlier reports
(Strong et al., 2008; Miller et al., 2011). The diet for controls and ra-
pamycin-treated mice was irradiated Purina 5LG6, which contains 4%
fat and 18% protein. In this study encapsulated rapamycin was
administered, from 9 months of age unless otherwise indicated, to
mice at doses of 4.7, 14, or 42 parts per million in food (calculated
on the basis of the equivalent mass of unencapsulated rapamycin).
The 14 ppm dose has previously been shown to extend lifespan when
started at 9 or at 20 months of age (Harrison et al., 2009; Miller
et al., 2011); a lifespan study at the 4.7 and 42 ppm dose levels is
under way. Serological assessment of sentinel mice was conducted at
least quarterly to evaluate the possibility of infection in the colonies,
and all such tests were negative throughout the period of testing. All
of the data presented in this report are from mice housed at the Uni-
versity of Michigan (UM), except that the data on spontaneous activ-
ity were obtained from equal numbers of mice at UM, the Jackson
Laboratory (TJL, Bar Harbor, ME, USA), and the University of Texas
Health Science Center (UT, San Antonio, TX, USA), and data on rapa-
mycin levels in serum were obtained from mice originally produced at
TJL and then shipped to UT for evaluation.
Necropsy procedures
Complete necropsies were performed on each mouse using standard
established protocols (Harrison et al., 2009). All grossly visible lesions
were recorded. All major organs were dissected and fixed in 10% forma-
lin. A standard set of tissues was processed, sectioned, and stained with
haematoxylin and eosin from each mouse. Any gross lesions noted in the
necropsy were also examined histologically. The standard set of tissues
was determined by past experience and previous studies of aging mice
(Mohr et al., 1996; Harrison et al., 2009; Miller et al., 2011). Liver,
spleen, pancreas, kidney, adrenal, heart, skeletal muscle, lung, thyroid,
and reproductive tract were examined from each mouse. All lesions were
recorded and specific lesions associated with aging were identified and
scored based on severity.
Cataract assessment
Mice were tested at age 20 months for lens opacity using a handheld slit
lamp after pupillary dilation with one drop of 1% tropicamide. Opacity
was scored on a scale from 0 (no evidence of cataract) to 3 (severe) for
each eye separately, and the mean score from the left and right eye was
used as an index of cataract severity.
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Tendon evaluation
Previous work has shown that mouse TA tendons stiffen and lose vis-
cous properties in a region-dependent manner with old age, with the
most pronounced changes occurring in the region nearest to the mus-
cle (proximal region). Therefore, mechanical properties were deter-
mined for the proximal region of the tendons, as previously described
(Wood et al., 2011). Briefly, tibialis anterior (TA) muscle-tendon units
(MTUs), consisting of the TA muscle, TA tendon, and 1st metatarsal,
were extracted and mounted in our custom-made tensile tester and
25 lm polystyrene beads brushed along the tendon to serve as optical
markers for strain measurements. The MTUs were immersed in PBS,
and the cross-sectional area was determined at six points along the
tendon. Tendons were subjected to a load–unload cycle of 10% grip-
to-grip strain at a constant strain rate of 0.01 s)1. Synchronized force
and image recordings were obtained during testing, and bead posi-
tions were tracked using Metamorph software. Stresses and nominal
strains were calculated for the proximal tendon region. The maximum
slope of the stress–strain response during the loading phase, termed
Maximum Tangent Modulus, was determined and taken as our mea-
sure of tendon stiffness. Hysteresis area, which is a measure of tendon
viscous properties, was calculated as the difference between the area
under the loading curve and the area under the unloading curve
expressed as a percentage of the area under the loading curve.
Spontaneous activity
We used an Accuscan system, as in (Miller et al., 2011), to evaluate activ-
ity. Total number of laser-beam breaks over a 50-h test interval was taken
as the index of activity and a change score calculated for each mouse that
had been measured at both 7 and 18 months of age. Experiments were
performed in parallel at three test sites (UM, TJL, UT) and then pooled for
analysis. For males, the data set included 113 control animals and 57–58
mice in each of the rapamycin groups. For females, the data included 142
controls and 74–82 mice in each of the rapamycin groups.
Statistical methods
We first tested in each case to see whether there was an age effect
in males and in females. If we found an age effect in one sex only,
then we evaluated rapamycin effects in that gender only. If there
was an age effect in each sex, we then tested for rapamycin effects
in the data pooled across sex. Effects of age on the frequency of spe-
cific lesions were evaluated using Fisher’s Exact Test in comparisons
of young to old controls. Effects of rapamycin on lesion frequency
were evaluated by Fisher’s Exact Test either by comparison of old
controls to mice treated with one dose of rapamycin, or pooled
across all rapamycin doses as described in the text. Cuzick’s nonpara-
metric test for trends (Cuzick, 1985) was used to evaluate signifi-
cance of differences among the four groups of old mice at four
levels of rapamycin (zero, low, mid, or high). Hypotheses about para-
metric data, such as the measures of tendon elasticity, were evalu-
ated by unpaired t-test. Two-tailed tests were used throughout. Other
statistical details are given in the text as appropriate.
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